STAAR Surgical Company (STAA) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Medical - Instruments & Supplies
EV/EBITDA
↓
N/A
—
5yr avg: 69.35
30Y Low10.7·High96.6
P/FCF
↓
N/A
—
5yr avg: 142.54
30Y Low43.9·High148.9
P/B Ratio
↓
4.15
↓-41% vs avg
5yr avg: 7.00
30Y Low1.4·High19.3
ROE
↓
-21.7%
↑-2529% vs avg
5yr avg: 0.9%
30Y Low-89%·High21%
Debt/EBITDA
↑
N/A
—
5yr avg: 0.86
30Y Low0.6·High9.7
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
STAA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
STAAR Surgical Company currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.4B | $1.2B | $1.2B | $1.5B | $2.4B | $4.5B | $3.8B | $1.6B | $1.4B | $636M | $438M |
| Enterprise Value | $1.3B | $1.1B | $1.1B | $1.4B | $2.3B | $4.3B | $3.7B | $1.5B | $1.3B | $623M | $430M |
| P/E Ratio → | -17.80 | — | — | 72.58 | 60.67 | 182.60 | 660.17 | 114.60 | 284.18 | — | — |
| P/S Ratio | 5.99 | 4.89 | 3.79 | 4.78 | 8.43 | 19.59 | 23.24 | 10.74 | 11.41 | 7.01 | 5.31 |
| P/B Ratio | 4.15 | 3.40 | 2.99 | 4.00 | 7.13 | 17.46 | 19.26 | 10.08 | 10.68 | 14.80 | 11.54 |
| P/FCF | — | — | — | — | 136.13 | 148.94 | 302.77 | 103.24 | 134.45 | 351.72 | — |
| P/OCF | — | — | 75.63 | 105.70 | 67.11 | 102.71 | 181.32 | 62.50 | 110.81 | 222.77 | 417.13 |
P/E links to full P/E history page with 30-year chart
STAA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.41 | 3.45 | 4.33 | 8.23 | 18.86 | 22.37 | 10.00 | 10.62 | 6.88 | 5.22 |
| EV / EBITDA | — | — | — | 42.00 | 48.47 | 117.57 | 370.76 | 96.57 | 145.29 | — | — |
| EV / EBIT | — | — | — | 49.66 | 53.46 | 130.41 | 540.28 | 126.71 | 199.57 | — | — |
| EV / FCF | — | — | — | — | 132.98 | 143.41 | 291.48 | 96.17 | 125.09 | 344.93 | — |
STAA Profitability
Margins and return-on-capital ratios measuring operating efficiency
STAAR Surgical Company earns an operating margin of -19.2%. Operating margins have compressed from 8.7% to -19.2% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -21.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 76.2% | 76.2% | 76.3% | 78.4% | 78.5% | 77.5% | 72.4% | 74.5% | 73.8% | 70.9% | 70.8% |
| Operating Margin | -19.2% | -19.2% | -4.0% | 8.7% | 15.4% | 14.5% | 4.1% | 7.9% | 5.3% | -4.0% | -15.4% |
| Net Profit Margin | -33.6% | -33.6% | -6.4% | 6.6% | 13.9% | 11.9% | 3.6% | 9.4% | 4.0% | -2.4% | -14.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -21.7% | -21.7% | -5.2% | 5.9% | 13.3% | 12.1% | 3.3% | 9.6% | 5.7% | -5.3% | -31.6% |
| ROA | -16.6% | -16.6% | -4.0% | 4.7% | 10.4% | 9.1% | 2.5% | 7.5% | 4.2% | -3.2% | -18.9% |
| ROIC | -13.2% | -13.2% | -3.6% | 8.1% | 17.7% | 34.1% | 9.7% | 21.3% | 15.3% | -8.9% | -31.2% |
| ROCE | -11.0% | -11.0% | -2.9% | 7.1% | 13.2% | 13.0% | 3.5% | 7.6% | 7.0% | -7.8% | -28.3% |
STAA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $153M exceeds total debt of $38M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.11 | 0.11 | 0.10 | 0.09 | 0.09 | 0.12 | 0.05 | 0.06 | 0.04 | 0.15 | 0.18 |
| Debt / EBITDA | — | — | — | 1.08 | 0.64 | 0.87 | 1.09 | 0.61 | 0.59 | — | — |
| Net Debt / Equity | — | -0.33 | -0.27 | -0.38 | -0.16 | -0.65 | -0.72 | -0.69 | -0.74 | -0.29 | -0.19 |
| Net Debt / EBITDA | — | — | — | -4.43 | -1.15 | -4.53 | -14.36 | -7.10 | -10.88 | — | — |
| Debt / FCF | — | — | — | — | -3.15 | -5.53 | -11.29 | -7.07 | -9.37 | -6.79 | — |
| Interest Coverage | — | — | — | — | — | 877.34 | — | — | — | -32.42 | -110.04 |
Net cash position: cash ($153M) exceeds total debt ($38M)
STAA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
STAAR Surgical Company's current ratio of 4.55x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 3.74x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 5.62x to 4.55x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.55 | 4.55 | 5.23 | 5.62 | 6.03 | 5.56 | 5.25 | 5.07 | 5.47 | 2.82 | 2.37 |
| Quick Ratio | 3.74 | 3.74 | 4.62 | 5.08 | 5.56 | 5.21 | 4.81 | 4.57 | 4.86 | 2.13 | 1.67 |
| Cash Ratio | 2.74 | 2.74 | 3.28 | 3.39 | 4.09 | 4.09 | 3.70 | 3.48 | 3.75 | 0.97 | 0.66 |
| Asset Turnover | — | 0.52 | 0.62 | 0.66 | 0.68 | 0.67 | 0.64 | 0.72 | 0.74 | 1.33 | 1.26 |
| Inventory Turnover | 1.03 | 1.03 | 1.72 | 1.99 | 2.53 | 3.00 | 2.49 | 2.23 | 1.94 | 1.98 | 1.62 |
| Days Sales Outstanding | — | 83.24 | 92.16 | 110.92 | 84.67 | 73.73 | 78.67 | 79.19 | 76.40 | 71.92 | 72.37 |
STAA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
STAAR Surgical Company returns 0.5% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | 1.4% | 1.6% | 0.5% | 0.2% | 0.9% | 0.4% | — | — |
| FCF Yield | — | — | — | — | 0.7% | 0.7% | 0.3% | 1.0% | 0.7% | 0.3% | — |
| Buyback Yield | 0.5% | 0.6% | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% |
| Total Shareholder Yield | 0.5% | 0.6% | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% |
| Shares Outstanding | — | $50M | $49M | $49M | $49M | $49M | $48M | $47M | $45M | $41M | $40M |
Peer Comparison
Compare STAA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 STAAYou | $1B | -17.8 | — | — | 76.2% | -19.2% | -21.7% | -13.2% | — |
 ALGN | $12B | 30.8 | 14.4 | 25.4 | 68.3% | 15.3% | 10.4% | 15.4% | 0.1 |
 LNTH | $7B | 31.1 | 17.2 | 19.5 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 TMDX | $3B | 15.5 | 19.1 | 19.5 | 59.9% | 17.9% | 54.2% | 18.8% | 3.5 |
 EW | $50B | 46.9 | 26.4 | 37.1 | 78.1% | 27.0% | 10.5% | 15.5% | 0.4 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
 ATRC | $1B | -118.5 | 79.6 | 29.8 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 |
 NVCR | $2B | -11.2 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 IRTC | $3B | -75.3 | — | 99.6 | 70.6% | -4.9% | -36.6% | -5.2% | — |
 ABT | $153B | 11.5 | 16.0 | 24.0 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
 BSX | $66B | 22.9 | 20.4 | 18.0 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
STAA — Frequently Asked Questions
Quick answers to the most common questions about buying STAA stock.
What is STAAR Surgical Company's P/E ratio?
STAAR Surgical Company's current P/E ratio is -17.8x. The historical average is 74.9x.
What is STAAR Surgical Company's ROE?
STAAR Surgical Company's return on equity (ROE) is -21.7%. The historical average is -13.5%.
Is STAA stock overvalued?
Based on historical data, STAAR Surgical Company is trading at a P/E of -17.8x. Compare with industry peers and growth rates for a complete picture.
What are STAAR Surgical Company's profit margins?
STAAR Surgical Company has 76.2% gross margin and -19.2% operating margin.